生产企业：Cellenkos, Inc.
FDA granted Fast Track designation to CK0803, an investigational allogeneic cord blood-derived T-regulatory (Treg) cell therapy from Cellenkos, Inc., for the treatment of amyotrophic lateral sclerosis (ALS) — the first Treg product to receive Fast Track designation for ALS.
FDA granted Fast Track designation to CK0803, an investigational allogeneic cord blood-derived T-regulatory (Treg) cell therapy from Cellenkos, Inc., for the treatment of amyotrophic lateral sclerosis (ALS) — the first Treg product to receive Fast Track designation for ALS.
共 1 项相关疾病
